000 01997cam  2200385zi 4500
0019.907333
003CaOODSP
00520221107181348
006m     o  d f      
007cr cn|||||||||
008220126e202202##oncd    obs  f000 0 eng d
020 |a9780660417950
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH82-29/3-2022E-PDF
24500|aAlignment among public formularies in Canada, part 3 : |bmedicines assessed by the common drug review.
264 1|aOttawa, ON : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |cFebruary 2022.
264 4|c©2022
300 |a1 online resource (iii, 21 pages) : |bcolour charts
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Concordance des listes de médicaments des régimes publics au Canada, partie 3 : médicaments évalués par le programme commun d'évaluation des médicaments.
500 |aIssued also in HTML format.
504 |aIncludes bibliographical references.
520 |a"This is the last report in a three-part PMPRB series that explores current overlaps and gaps in Canadian public drug plan formularies"--Executive summary, page ii.
650 0|aPharmaceutical services insurance|zCanada|vStatistics.
650 0|aDrugs|zCanada|vStatistics.
650 0|aPharmaceutical policy|zCanada.
655 7|aStatistics|2lcgft
7101 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body.
77508|tConcordance des listes de médicaments des régimes publics au Canada, partie 3 : |w(CaOODSP)9.907335
85640|qPDF|s2.60 MB|uhttps://publications.gc.ca/collections/collection_2022/cepmb-pmprb/H82-29-3-2022-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/formularies-part3-medicines-assessed.html